Adapted Physical Activity for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Trastuzumab Against HER2 (APACAN2): A Protocol for a Feasibility Study.

Ginzac, Angeline; Bernadach, Maureen; Molnar, Ioana; Duclos, Martine; Thivat, Emilie; Durando, Xavier

Ginzac, Angeline; Bernadach, Maureen; Molnar, Ioana; Duclos, Martine; Thivat, Emilie; Durando, Xavier.

Afiliação

Ginzac A; INSERM U1240 IMoST, Université Clermont Auvergne, Clermont-Ferrand, France.
Bernadach M; Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand, France.
Molnar I; Centre d'Investigation Clinique UMR501, Clermont-Ferrand, France.
Duclos M; Service d'Oncologie Médicale, Centre Jean PERRIN, Clermont-Ferrand, France.
Thivat E; INSERM U1240 IMoST, Université Clermont Auvergne, Clermont-Ferrand, France.
Durando X; Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand, France.

Front Oncol ; 11: 744609, 2021.

Article em En | MEDLINE | ID: mdl-34966667

Palavras-chave

HER2-directed therapy; HER2-positive breast cancer; adapted physical activity; feasibility study; neoadjuvant chemotherapy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Idioma: En Revista: Front Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google